A study for quality evaluation of Lysimachiae herba from different origins based on fingerprint-activity relationship modeling and multi-component content determination.

Cholestatic liver injury Different origins Fingerprint Lysimachiae herba Quality evaluation

Journal

Journal of ethnopharmacology
ISSN: 1872-7573
Titre abrégé: J Ethnopharmacol
Pays: Ireland
ID NLM: 7903310

Informations de publication

Date de publication:
03 Feb 2024
Historique:
received: 01 12 2023
revised: 24 01 2024
accepted: 28 01 2024
medline: 6 2 2024
pubmed: 6 2 2024
entrez: 5 2 2024
Statut: aheadofprint

Résumé

Lysimachiae Herba (LH), called Jinqiancao in Chinese, is a commonly used traditional Chinese medicine in clinical practice. Doctors in the Qing Dynasty recorded that it tastes bitter, sour, and slightly cold, and it belongs to the liver, gallbladder, kidney, and bladder meridians. It has the effects of removing dampness and jaundice, eliminating gallstones, and reducing blood stasis. Because of its potent pharmacological effects, it is extensively utilized in the treatment of hepatobiliary and urinary system stones, jaundice, hepatitis, and cholecystitis. Although LH is included in "Sichuan authentic Chinese herbal medicine records", the quality of it from different origins still lacks reliable evaluation methods, which is difficult to reflect the high quality of LH from Sichuan. This study aimed to establish a fingerprint-activity relationship model between the fingerprint of LH and its protective effect on cholestatic liver injury, and to evaluate the quality of LH from Sichuan and Guizhou by multivariate statistical analysis. 20 batches of LH samples were collected from Sichuan and Guizhou. Characteristic fingerprints of samples were established by UHPLC-Triple TOF-MS/MS and the chemical pattern recognition analysis was carried out by HCA. Then, a rat model of cholestatic liver injury was established by intragastric administration of ANIT. Combined with the common peak information of fingerprint and pharmacodynamic index results, GCA and BCA were used to screen the efficacy markers. Finally, based on UHPLC-QTRAP-MS/MS, the content of efficacy markers was simultaneously determined, and the overall quality of LH from two origins was evaluated by PCA and TOPSIS. In the fingerprint of 20 batches of LH, 15 common peaks were identified in the negative ion mode, and the similarity was between 0.887 and 0.981. Pharmacological results showed that, compared with the control group, the content of AST, ALT, ALP, TBA, TBIL, and MDA in serum increased, and the content of GSH and SOD activity decreased after 48 h of ANIT administration. In addition, compared to the model group, different doses of LH from the two origins could decrease the serum levels of AST, ALT, ALP, TBA, TBIL, and MDA, raise the levels of GSH and SOD activity, reduce the infiltration range of inflammatory cells, and improve the cholestatic liver injury in rats. Among them, the pharmacodynamic indices of the SCHD group were significantly better. GCA and BCA showed that a total of 7 constituents related to the efficacy were screened, which were proanthocyanidin B1, ferulic acid, hyperoside, astragalin, nicotiflorin, afzelin, and kaempferol. Besides, the content of 7 active constituents in samples from Sichuan was higher than that from Guizhou, indicating that the quality of samples from Sichuan may be better, consistent with the result of the pharmacological experiment. The quality and efficacy of LH from different origins were stable, and all of them had protective effects on cholestatic liver injury in rats. The method established in this study is accurate and reliable, and it can be used to comprehensively evaluate the internal quality of LH.

Identifiants

pubmed: 38316219
pii: S0378-8741(24)00139-9
doi: 10.1016/j.jep.2024.117840
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

117840

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Yongyi Zhou (Y)

College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China. Electronic address: zyy18851091328@163.com.

Cuihua Chen (C)

College of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China. Electronic address: 290392@njucm.edu.cn.

Jiahuan Yuan (J)

College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.

Jia Xue (J)

College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.

Haijie Chen (H)

College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.

Xunhong Liu (X)

College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China; Jiangsu Province Engineering Research Center of Classical Prescription, Nanjing 210023, China. Electronic address: 300100@njucm.edu.cn.

Zhichen Cai (Z)

College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.

Nan Wu (N)

College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.

Wei Yang (W)

College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.

Jianming Cheng (J)

College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China; Jiangsu Province Engineering Research Center of Classical Prescription, Nanjing 210023, China.

Classifications MeSH